Rita, Indo-Pacific bottlenose dolphin at Hong Kong's Ocean Park, dies at 24
A 24-year-old Indo-Pacific bottlenose dolphin named Rita has died at Hong Kong's Ocean Park after showing signs of fatigue and a loss of appetite.
The marine mammal had lived in the park for about 13 years after she was transferred from Tunisia. Investigations into her death are ongoing.
'Rita was a playful animal who got along well with her dolphin and human mates, and was a beloved animal ambassador living in the Marine Mammal Breeding and Research Centre next to the Ocean Park Veterinary Centre,' a park spokesman said.
Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team.
She had refused to eat and showed signs of tiredness since Friday.
The park said that veterinarians performed thorough examinations and blood tests on the dolphin, which caretakers looked after around the clock.
But her health conditions worsened and she died on Sunday afternoon.
The park has conducted a necropsy to determine the cause of death, while further laboratory tests are under way.
The spokesman said that students had learned about and appreciated the natural behaviour and daily care of dolphins up close through guided tours, and were inspired to contribute to marine conservation.
'The park expresses its gratitude to Rita for conveying conservation messages to visitors. She will forever hold a special place in our hearts and memories,' he said.
Rita was transferred to Hong Kong from Friguia Park in Tunisia in November 2012, after the facility closed its dolphin show, according to Ceta-Base, an online database of captive-held cetaceans across the world.
She gave birth to a male calf named Rati in September 2015.
In 2021, Ocean Park announced that Milo, a seven-year-old female Indo-Pacific bottlenose dolphin, died after suffering acute haemorrhagic enteritis, or inflammation of the intestines.
More from South China Morning Post:
For the latest news from the South China Morning Post download our mobile app. Copyright 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 days ago
- Malaysian Reserve
Illuminating ctDNA-MRD: Gene Solutions' K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology
DA NANG, Vietnam, May 31, 2025 /PRNewswire/ — May 9-11, 2025, Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP). Under the theme 'Empowering the Potential of ctDNA-MRD,' 16 distinguished speakers and panelists shared clinical insights, breakthrough research, and innovative strategies for integrating ctDNA-MRD into cancer practice. 'While ctDNA and MRD are invisible to the eye, K-CONNECT APAC 2025 shed transformative light on their potential through regional collaboration and clinical innovation,' said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. 'Illuminating ctDNA-MRD means revealing actionable insights that spark hope, clarity, and progress through molecular insights to transform precision oncology.' 'K-CONNECT APAC 2025 was a transformative moment for precision oncology in the Asia-Pacific, bringing together diverse expertise to translate ctDNA-MRD advancements into real-world clinical impact' said Professor Nick Pavlakis, Co-Chair of the summit and a leading medical oncologist from Australia. 'This summit has set a new benchmark for collaborative innovation, paving the way for personalized cancer care across the region' A First-of-Its-Kind Gathering in Asia-Pacific Gene Solutions, a regional pioneer in ctDNA-MRD testing, has supported over 6,000 cancer patients via its next generation comprehensive AI-powered K-TRACK® and K-4CARE® platforms. K-CONNECT APAC 2025 showcased its role in fostering cross-border expertise to accelerate adoption of precision diagnostics. The summit featured three key sessions shared by 16 esteemed experts K-CONNECT ACADEMIC Session: The Importance of ctDNA-MRD and CGP in Precision Oncology Unique Combination of Genomic & Transcriptomic Profiling with ctDNA-MRD Monitoring Key findings from Asia's First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors. K-CONNECT CASE SHARING Session ctDNA-MRD Applications & Real-World Case Sharing in Colorectal, Lung and Breast cancers. K-CONNECT NEXT LANDMARK Session Genetic Testing Guided Personalized Immunotherapy in Refractory Solid Tumors. Triad of Impact– A Multi-omic Solution to Advance Precision Oncology Innovation. Beyond an Event — Establishing a Platform for Ongoing Impact K-CONNECT is evolving into a regional hub for knowledge exchange, clinical collaborations, and precision oncology innovation acceleration. Upcoming initiatives include: K-CONNECT Webinar Series – Ongoing expert-led case discussions Clinical Trials Collaboration – Cross-border partnerships with biopharma and research institutions Experience ctDNA-MRD Program – Hands-on implementation support for clinicians Knowledge Hub – A digital platform for APAC oncology insights Shaping the Future of Cancer Care K-CONNECT APAC 2025 solidified Gene Solutions' leadership in genetic testing and its commitment to advancing equitable access to innovative solutions to improve patient outcomes. By fostering collaboration and showcasing real-world impact, the summit laid the foundation for a more connected, data-driven, and patient-centered future in cancer care across the Asia-Pacific. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: MEDIA CONTACT: pr@
The Sun
3 days ago
- The Sun
Humansa and i-Cognitio Sciences Unveil the World's First AI-Powered Retinal Imaging for Alzheimer's Risk Detection
HONG KONG SAR - Media OutReach Newswire - 29 May 2025 - Humansa, Asia's leading health and longevity center, is proud to announce the launch of its ground-breaking BrainSpark Program, a brain health program in collaboration with i-Cognitio Sciences, a spin-off company from the Chinese University of Hong Kong (CUHK) founded by Prof. Vincent Mok. This revolutionary program incorporates the world's first artificial intelligence (AI) model capable of detecting risk of Alzheimer's disease using fundus photographs alone, offering a non-invasive and accessible solution to address the growing global challenge of cognitive decline and dementia. The Humansa BrainSpark Program is a timely response to the alarming statistics in developed Asia-Pacific regions, where the mean life expectancy has reached 85 years. Yet, 1 in 3 individuals aged 85 or above may suffer from dementia, a devastating disease that robs individuals of their independence and quality of life. Research shows that 45% of dementia cases can be prevented or delayed by optimizing modifiable risk factors, making early detection and personalized interventions critical. A Revolutionary Approach to Brain Health The Humansa BrainSpark Program embodies a proactive approach to brain health by offering: Comprehensive Brain Health Assessment: Powered by state-of-the-art AI retinal imaging technology (i-Cog Brain Health) led and developed by Prof. Vincent Mok's team, the program evaluates brain health and identifies early signals of Alzheimer's disease. The AI model, developed and validated using nearly 13,000 fundus photographs from 648 Alzheimer's patients and 3,240 cognitively normal subjects, demonstrated accuracies ranging from 80% to 92% among various datasets of multi-ethnicities and multi-countries. The study was led by CUHK in collaboration with Universities in Singapore (National University of Singapore, Duke-National University, Nanyang Technological University), China (Tsinghua University), US (Mayo Clinic) and UK (Queen's University Belfast). The findings were published in the prestigious Lancet Digital Health journal in 2022. Tailor-Made Lifestyle Solutions: The Humansa BrainSpark Program offers tailor-made solutions that go beyond standard care, focusing on early detection and prevention of major chronic diseases, including Alzheimer's and dementia. By combining advanced AI technology with personalized care, Humansa provides lifestyle interventions, medical support, and preventive strategies tailored to each individual's unique risk profile. Additionally, Humansa's signature membership program offers a holistic anti-aging solution. This comprehensive package includes personalized recommendations on supplements, the frequency of restorative therapies, and other longevity strategies, empowering individuals to take proactive steps toward better brain health and overall well-being. Professor Vincent Mok, Founding Director of i-Cognitio Sciences and Mok Hing Yiu Professor of Medicine of CUHK explains, 'The retina is an extension of the brain, and through non-invasive fundus photography, we can detect changes in the blood vessels and nerves of the retina that are associated with Alzheimer's disease. These changes can appear 10–15 years before symptoms develop, giving us a critical window for early intervention. This AI model can identify early microvascular changes associated with Alzheimer's disease that may not be detected even by conventional MRI, making it a powerful tool for identifying high-risk cases in both clinical and community settings.' Regarding the Humansa BrainSpark Program, Professor Mok adds, 'This program is an innovative initiative that combines cutting-edge AI technology with personalized care approach. It encourages individuals to take proactive steps to protect their brain health, enabling early preventive treatments and lifestyle changes that can slow cognitive decline and preserve quality of life.' Aligning with Humansa's Methodology to Longevity The newly launched Humansa BrainSpark Program is a cornerstone of Humansa's methodology to longevity and its signature Future Health Program, which emphasizes prevention, early detection, and personalized care. Cognitive function is a critical pillar of Humansa's longevity strategy, as maintaining brain health is essential for living a long, independent, and fulfilling life. Don So, CEO of Humansa, shares, 'At Humansa, we believe that aging is not a passive process—it's a skill, a choice, and a science. Cognitive function is at the heart of our longevity strategy because it directly impacts an individual's ability to live independently and enjoy life to the fullest. The symptoms may show up decades later, but the seeds are often planted much earlier. The silent inflammation, the unchecked insulin resistance, and the daily choices—small and seemingly insignificant—that quietly shape your destiny. The Brain Health Program is a testament to our commitment to empowering individuals to live longer, healthier lives by providing them with the tools and knowledge to protect their brain health.' A Call to Action The Humansa BrainSpark Program combines cutting-edge technology with personalized care, offering individuals a proactive way to protect their brain health and live longer, healthier lives.
The Star
7 days ago
- The Star
Hong Kong warned of surge in inflammatory bowel disease rates
The number of Hongkongers suffering from incurable chronic gut conditions could surge by 150 per cent over a 20-year period due to unhealthy diets, high in sugar and fat, according to a global study. Scientists from the study that was co-led by researchers from Hong Kong and Canada raised the alarm after a projection model estimated that the prevalence of inflammatory bowel disease in the city would rise from 40 cases per 100,000 people in 2014 to 100 in 2034. 'The 150 per cent increase in the total number in terms of prevalence – this is quite scary,' said Professor Ng Siew Chien, associate dean of the Chinese University of Hong Kong's medical school and an expert in gastroenterology who co-led the study. Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team. 'We call this probably an explosion.' Researchers found that the rates were related to economic development and that less developed places, such as Malaysia and mainland China, had lower rates than Hong Kong, although they were also trending upwards. IBD refers to a group of conditions that cause swelling and inflammation of tissue in the digestive tract, with Crohn's disease and ulcerative colitis being the two most common types. Common symptoms of such conditions include diarrhoea, abdominal pains and cramps, and blood in the stool. IBD sufferers are also more likely to develop serious illnesses such as colon cancer. The researchers' projection model is based on real-world data collected from more than 500 studies in 82 regions that took place between 1920 and 2024. It also anticipated a rise in the local incidence rate for IBD, which involves the number of new cases per 100,000 people. While the rate in Hong Kong was 0.1 in 1985, it rose to about three in 2013 and is estimated to have exceeded four in 2023. The figures placed the city in the second part of a four-stage model outlined in the study, meaning it was experiencing a phase of 'acceleration in incidence' in IBD cases. Other jurisdictions that were seeing similar trends to Hong Kong included many relatively newly industrialised nations in Asia and Latin America, such as mainland China, Japan and South Korea. In the mainland, the rate of new cases rose from two per 100,000 people in 2010, to 15 in 2020. The total number of IBD patients in the country is expected to exceed 1.5 million by this year, according to Ng. The study, which was published in top scientific journal Nature last month, placed countries with low incidence and prevalence rates, such as many places in Africa, in the stage one category. Most countries in North America, Europe and Oceania were classified as being in stage three, meaning the number of new cases had already slowed down, but the total number of patients had steadily increased. While such conditions are not fatal and can be managed with medications and treatments, they cannot be cured. Serious cases can require surgery to remove a patient's colon and rectum, who must then carry a pouch to collect their waste. The late Shinzo Abe resigned as the prime minister of Japan in 2020 due to his struggles with ulcerative colitis. Study co-leader Professor Gilaad Kaplan, a gastroenterologist from the medical school of Canada's University of Calgary, said increases in new cases of IBD correlated with economic advancement. 'The earlier a country transitions into economic advancements, the earlier we see that trigger into stage two,' he said. Kaplan said that while higher incidence and prevalence rates were due to improved detection and diagnostic tools in economically advanced regions, environmental factors also played a crucial role. A person's diet was one of the strongest pillars under the category of environmental factors that contributed to a rise in cases, Kaplan and Ng said. Diets that were high in fat, sugar, ultra-processed foods, additives and colourings could change the health of a person's gut, she said. 'These foods actually affect our gut microbiome, which is the bacteria and viruses inside our gut,' the researcher said. 'They can induce [and] increase bacteria that can cause inflammation ... These bacteria produce toxins and chemicals inside the gut, and then it makes the gut very thin.' Ng explained that the resulting toxins and inflammatory responses inside the gut could then disturb one's immune system. She added that a growing number of IBD patients could see the local healthcare system face an increased economic burden, citing her own separate analysis on the topic. The academic noted that the average medical cost for a patient with the condition was about HK$40,000 to HK$50,000 (US$6,380) a year, about twice the amount paid by someone suffering from type 2 diabetes. Kaplan, meanwhile, said that IBD patients would get older and become more challenging to manage if they developed other conditions such as diabetes or dementia. Both researchers called for preventive actions to slow down IBD's growing prevalence and incidence rates. 'Our models show that if we can prevent the incidence of new diagnoses, even just by a small amount, that has a huge impact on blunting the overall growth or prevalence of the disease,' Kaplan said. He added that people could stave off such conditions by adopting a healthy, whole food diet, while officials could create policies that increased the availability of healthy foods. Sharing her tips on preventing the condition among the children of IBD patients, Ng said: 'Less processed food; just cook everything from scratch. Try not to use so many antibiotics if you can, because that changes the gut microbiome as well.' More from South China Morning Post: For the latest news from the South China Morning Post download our mobile app. Copyright 2025.
